Enzelkitug (Not yet branded)

Description

Enzelkitug is a monoclonal antibody targeting CD39 (also known as NTPDase1/ENTPD1), an ectonucleotidase expressed on immunosuppressive cells within the tumor microenvironment. It has been explored in colorectal cancer as part of a tumor-agnostic Phase 1 program evaluating its activity both as a single agent and in combination with checkpoint inhibitors. The drug is designed to relieve adenosine-mediated immune suppression in solid tumors, including CRC, where the immunosuppressive tumor microenvironment frequently limits the efficacy of immunotherapy approaches.

Mechanism of Action

Enzelkitug blocks CD39, an enzyme on regulatory T cells, myeloid cells, and tumor cells that catalyzes the hydrolysis of extracellular ATP into AMP, which is subsequently converted to immunosuppressive adenosine by CD73. By inhibiting CD39, enzelkitug reduces adenosine production in the tumor microenvironment, thereby restoring pro-inflammatory ATP signaling and enhancing cytotoxic T-cell activity against tumor cells. This mechanism is intended to synergize with PD-1/PD-L1 checkpoint inhibitors by simultaneously addressing two complementary arms of tumor immune evasion.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials